Stonebridge Financial Group LLC Acquires 10,990 Shares of Abbott Laboratories $ABT

Stonebridge Financial Group LLC raised its holdings in Abbott Laboratories (NYSE:ABT) by 28.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 49,984 shares of the healthcare product maker’s stock after acquiring an additional 10,990 shares during the period. Stonebridge Financial Group LLC’s holdings in Abbott Laboratories were worth $4,536,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Somerset Trust Co boosted its holdings in Abbott Laboratories by 1.0% in the 2nd quarter. Somerset Trust Co now owns 46,025 shares of the healthcare product maker’s stock worth $4,176,000 after buying an additional 458 shares during the period. Dogwood Wealth Management LLC lifted its position in shares of Abbott Laboratories by 25.7% during the second quarter. Dogwood Wealth Management LLC now owns 611 shares of the healthcare product maker’s stock worth $55,000 after acquiring an additional 125 shares in the last quarter. Burkett Financial Services LLC boosted its holdings in shares of Abbott Laboratories by 21.1% in the second quarter. Burkett Financial Services LLC now owns 1,428 shares of the healthcare product maker’s stock worth $130,000 after acquiring an additional 249 shares during the period. CX Institutional grew its position in shares of Abbott Laboratories by 17.8% in the second quarter. CX Institutional now owns 94,489 shares of the healthcare product maker’s stock valued at $8,574,000 after purchasing an additional 14,257 shares in the last quarter. Finally, Miller Global Investments LLC raised its stake in shares of Abbott Laboratories by 54.3% during the 2nd quarter. Miller Global Investments LLC now owns 1,611 shares of the healthcare product maker’s stock valued at $146,000 after purchasing an additional 567 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Up 1.4%

Shares of ABT stock opened at $107.16 on Tuesday. The business has a 50-day moving average price of $93.84 and a two-hundred day moving average price of $100.33. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a market cap of $185.43 billion, a P/E ratio of 34.68, a price-to-earnings-growth ratio of 2.05 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company’s revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ABT. Piper Sandler restated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Leerink Partners cut their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Benchmark lowered their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Bank of America cut their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $118.17.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.